Aclaris Therapeutics enters amended at-the-market equity sales agreement with Leerink, Cantor
ACRS•Amended at-the-market equity sales agreement
Aclaris Therapeutics entered a second amended and restated at-the-market equity distribution agreement with Leerink Partners and Cantor Fitzgerald.
- Allows sales of common stock from time to time at the company’s discretion under a Form S-3 registration statement.
- Replaces the February 27, 2025 sales agreement that provided for up to USD 100 million of common stock sales.
- Sales agents to use commercially reasonable efforts based on company instructions; 3% commission on gross proceeds.
- No obligation to sell shares; program ends upon termination under the agreement’s terms.
